As the U.S. stock market reaches record highs, bolstered by inflation data that fuels hopes for interest rate cuts, investors are keenly exploring diverse opportunities. Penny stocks, often associated with smaller or newer companies, continue to present intriguing possibilities despite their seemingly outdated label. These stocks can offer significant growth potential when backed by strong financials and solid fundamentals, making them a noteworthy consideration for those looking to uncover hidden value in today's market landscape.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Dingdong (Cayman) (DDL) | $2.27 | $456.47M | ✅ 4 ⚠️ 0 View Analysis > |
| Waterdrop (WDH) | $1.89 | $676.31M | ✅ 4 ⚠️ 0 View Analysis > |
| WM Technology (MAPS) | $1.25 | $206.93M | ✅ 4 ⚠️ 2 View Analysis > |
| Puma Biotechnology (PBYI) | $4.50 | $228.68M | ✅ 3 ⚠️ 2 View Analysis > |
| Performance Shipping (PSHG) | $1.87 | $23.87M | ✅ 4 ⚠️ 2 View Analysis > |
| Golden Growers Cooperative (GGRO.U) | $5.00 | $79.78M | ✅ 2 ⚠️ 5 View Analysis > |
| Table Trac (TBTC) | $4.88 | $23.8M | ✅ 2 ⚠️ 2 View Analysis > |
| BAB (BABB) | $0.947 | $7.05M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (LCUT) | $4.20 | $90.63M | ✅ 3 ⚠️ 3 View Analysis > |
| TETRA Technologies (TTI) | $4.83 | $639.74M | ✅ 3 ⚠️ 2 View Analysis > |
Click here to see the full list of 377 stocks from our US Penny Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
ProKidney (PROK)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: ProKidney Corp. is a clinical-stage biotechnology company focused on developing a cell therapy platform for treating multiple chronic kidney diseases in the United States, with a market cap of approximately $635.65 million.
Operations: No revenue segments are reported for this clinical-stage biotechnology company.
Market Cap: $635.65M
ProKidney Corp., a clinical-stage biotechnology firm, is navigating the challenges typical of penny stocks with its pre-revenue status and volatile share price. Despite being debt-free and having short-term assets exceeding liabilities, it faces significant hurdles such as unprofitability and inexperienced management. The company recently reported a net loss increase to US$33.29 million for the first half of 2025, while earnings are projected to decline over the next three years. However, ProKidney's ongoing Phase 3 trials for rilparencel show promise under FDA's accelerated approval pathway, potentially influencing future growth prospects in kidney disease treatment markets.
- Click here and access our complete financial health analysis report to understand the dynamics of ProKidney.
- Evaluate ProKidney's prospects by accessing our earnings growth report.
Dingdong (Cayman) (DDL)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Dingdong (Cayman) Limited operates as an e-commerce company in China and has a market cap of approximately $456.47 million.
Operations: The company generates revenue from its online retail operations, amounting to CN¥23.90 billion.
Market Cap: $456.47M
Dingdong (Cayman) Limited demonstrates potential within the penny stock landscape, underpinned by strong financial performance and strategic management. The company reported Q2 2025 revenue of CN¥5.98 billion, marking an increase from the previous year, with net income rising to CN¥107.19 million. Its earnings growth of 386.6% over the past year surpasses industry averages, supported by experienced leadership and a robust balance sheet featuring more cash than debt. Additionally, Dingdong's profitability has improved significantly over five years, showcasing high-quality earnings and stable volatility while trading below estimated fair value compared to peers in the consumer retailing sector.
- Take a closer look at Dingdong (Cayman)'s potential here in our financial health report.
- Assess Dingdong (Cayman)'s future earnings estimates with our detailed growth reports.
Tuya (TUYA)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Tuya Inc. operates as an AI cloud platform service provider in the People’s Republic of China with a market cap of approximately $1.52 billion.
Operations: The company's revenue is primarily generated from its Internet Software & Services segment, amounting to $318.49 million.
Market Cap: $1.52B
Tuya Inc. presents a compelling case in the penny stock realm with its recent transition to profitability, reporting a Q2 2025 net income of US$12.59 million and sales of US$80.13 million, up from the previous year. The company boasts strong financial health with short-term assets significantly exceeding liabilities and no debt burden over the past five years. While Tuya's return on equity is low at 2.9%, its earnings growth trajectory is promising, supported by an experienced management team and board of directors. However, dividend sustainability remains questionable as payouts are not well covered by earnings or cash flows.
- Navigate through the intricacies of Tuya with our comprehensive balance sheet health report here.
- Review our growth performance report to gain insights into Tuya's future.
Next Steps
- Unlock our comprehensive list of 377 US Penny Stocks by clicking here.
- Interested In Other Possibilities? Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Tuya might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com